ArticleCurrent health sciences journal
Colorectal Cancer: An Update on Treatment Options and Future Perspectives.
Article in Current health sciences journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient choice in colorectal cancer treatment - A systematic review and narrative synthesis of attribute-based stated preference studies.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2022Pooled it
- Article
- Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer.Cell death discovery · 2025Article
- α‑Phellandrene enhances the apoptosis of HT‑29 cells induced by 5‑fluorouracil by modulating the mitochondria‑dependent pathway.Oncology reports · 2024Article
- The Role of Tumor Parenchymal and Stromal Ratios in Colorectal Cancer.Journal of family & reproductive health · 2024Review
- New Materials Used for the Development of Anion-Selective Electrodes-A Review.Materials (Basel, Switzerland) · 2023Review
- TRIM55 inhibits colorectal cancer development via enhancing protein degradation of c-Myc.Cancer medicine · 2023Article
- Pyrazole-sulfonamide scaffold featuring dual-tail strategy as apoptosis inducers in colon cancer.Scientific reports · 2023Article
- Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.International journal of molecular sciences · 2022Review
- The pathogenic roles of lncRNA-Taurine upregulated 1 (TUG1) in colorectal cancer.Cancer cell international · 2022Review
- Filipinos' attitudes, barriers, and enablers on colorectal cancer screening: Insights from a qualitative research study.Cancer treatment and research communications · 2022Article
- Complement System: An Immunotherapy Target in Colorectal Cancer.Frontiers in immunology · 2022Review
- Bioinformatic Analysis of the Effect of Silver Nanoparticles on Colorectal Cancer Cell Line.BioMed research international · 2022Article
- Effects of Radiotherapy in Combination With Irinotecan and 17-AAG on Bcl-2 and Caspase 3 Gene Expression in Colorectal Cancer Cells.Journal of lasers in medical sciences · 2022Article
- Review
- Article
- Network Pharmacology-Based Study on the Mechanism of Gegen Qinlian Decoction against Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Risk Factors and Genetic Predisposition in Colorectal Cancer: A Study on Young and Old Adults.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Throughout the years, colorectal cancer has steadily become a global health problem. While other types of cancers have seen a decline in cases because of screening and vaccination programs, colorectal cancer has risen become the third most diagnosed cancer worldwide and, more worryingly, the second leading cancer-related cause of death. The introduction of targeted therapy has been widely considered a major paradigm shift in the treatment of colorectal cancer, which agents such as bevacizumab and cetuximab quickly becoming mainstay options in the treatment of locally advanced or metastatic disease. However, this type of treatment has also shown its limitations, with limited or no benefit for a large portion of the patients. With more and more knowledge being gathered on the molecular mechanisms which govern the malignant phenotype presented by colorectal cancer, scientists are engaged in a continuous effort to develop new therapies based on these discoveries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.